Nefam solution for injection 10 mg/ml 2ml x 5 ampoules — Made in Ukaraine — Free Delivery

Product description

Solution for injection "Nefam" is used for the following indications:

• postoperative analgesia as part of multimodal analgesia (nefopam also has a positive effect on preventing postoperative tremors);
• symptomatic treatment of acute pain conditions (trauma, pain after surgery, pain relief of renal and hepatic colic).

Structure

The active ingredient is nefopam hydrochloride (1 ml of nefopam hydrochloride 10 mg).

Excipients: sodium dihydrogen phosphate, dihydrate; sodium phosphate, dodecahydrate; water for injections.

Contraindications

Hypersensitivity to nefopam or other components of the preparation.

Children under 15 years of age - due to the lack of clinical trials.

Seizures or a history of seizures.

Risk of urinary retention associated with urethroprostatic disorders.

Risk of acute glaucomatous attack.

Simultaneous use of MAO inhibitors.

Mode of application

Therapy should be appropriate to the intensity of the pain syndrome and the patient's response.

Intramuscular injection. Nefam should be injected intramuscularly deeply. A dose of 20 mg is recommended per administration. If necessary, the introduction is repeated every 6 hours. The maximum daily dose is 120 mg.

Intravenous administration. "Nefam" should be administered as a long-term infusion for at least 15 minutes, the patient should be in the supine position to avoid such adverse reactions as nausea, dizziness, sweating. The dose per injection is 20 mg. If necessary, the introduction is repeated every 4 hours. The maximum daily dose is 120 mg.

Method of introduction

Nefam can be administered in a common solution for infusion (0.9% sodium chloride solution or 5% glucose solution). The optimal dilution ratio is one ampoule of the preparation in 50 ml of solution for infusion.

The course of treatment is no more than 8-10 days.

Application features

Pregnant

There is no data on the use of the preparation in pregnant women. For safety reasons, nefam should not be used during pregnancy.

Nefopam is excreted in breast milk in an amount that may affect newborns / breastfed infants. Nefam should not be used during breastfeeding.

Drivers

The risk of drowsiness during treatment should be taken into account, which may affect the ability to drive vehicles or operate machinery.

Overdose

Symptoms of anticholinergic origin: tachycardia, coma, convulsions, hallucinations.

Treatment: symptomatic treatment with cardiac and respiratory monitoring in a hospital setting.

Side effects

From the nervous system: very often (≥ 1/10) - drowsiness; often (≥ 1/100, <1/10) - dizziness.

From the side of the heart: often (≥ 1/100, <1/10) - tachycardia, palpitation.

From the digestive tract: very often (≥ 1/10) - nausea, vomiting; often (≥ 1/100, <1/10) - dry mouth.

On the part of the kidneys and urinary system: often (≥ 1/100, <1/10) - urinary retention.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 2 years.